Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma

Pathol Oncol Res. 2011 Mar;17(1):141-3. doi: 10.1007/s12253-010-9276-4. Epub 2010 Jul 14.

Abstract

Chemotherapy induced thrombopenia (CIT) is difficult to treat, as previous treatment options, including recombinant human thrombopoietin proved to be of limited efficacy. Here we report a case of a mantle cell lymphoma patient treated with intensive chemotherapy, who belongs to Yehova's witnesses and therefore did not accept platelet transfusions. At the time of severe thrombocytopenia (zero thrombocytes/ per mikroliter) and gastrointestinal bleeding, on day 13 following the start of hyperCVAD B chemotherapy, romiplostim treatment was given resulting in quick normalisation of the platelet count followed by thrombocytosis. Based on our observation in further studies modification of the dose and timing of romiplostim injection in CIT should be considered.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Male
  • Middle Aged
  • Receptors, Fc / therapeutic use
  • Recombinant Fusion Proteins / adverse effects*
  • Recombinant Fusion Proteins / therapeutic use
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / drug therapy*
  • Thrombopoietin / adverse effects*
  • Thrombopoietin / therapeutic use

Substances

  • Antineoplastic Agents
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim